VISTAGEN THERAPEUTICS, INC. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $23.00 million for the 12-month period ending 2021-03-31, per its 10-K filed 2021-06-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2021-06-29
- VISTAGEN THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $23.00M.
- VISTAGEN THERAPEUTICS, INC. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2014 was $100.70K.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2021-03-31 | $23.00M 10-K · filed 2021-06-29 |
| 2014-03-31 | $100.70K 10-K · filed 2015-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |